Physician profile
Evan Goldfischer
NPI 1639274699
$314,124.64
in general payments reported to CMS, 2019-2025
64 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $42K · 2021: $29K · 2022: $41K · 2023: $69K · 2024: $41K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $18K · Food and Beverage: $9,260 · Honoraria: $5,775 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,331.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,063.25 |
| Travel and Lodging | $17,869.38 |
| Food and Beverage | $9,260.37 |
| Honoraria | $5,775.00 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63,494.46 | 2019-2025 | |
| Janssen Biotech, INC. | $62,568.02 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Abbvie INC. | $49,517.20 | 2019-2025 | |
| Boston Scientific Corporation | $35,109.37 | 2019-2025 | Spaceoar System, General - Therapies, Rezum Generator |
| Astellas Pharma US INC | $12,960.43 | 2019-2025 | Xtandi, Veozah, Myrbetriq |
| Progenics Pharmaceuticals, INC. | $11,344.52 | 2021-2024 | Pylarify |
| Pfizer INC. | $11,324.64 | 2019-2025 | |
| Janssen Global Services, LLC | $9,041.64 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $8,086.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $7,036.56 | 2020-2024 | Lynparza |
| Myovant Sciences INC. | $6,760.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $6,558.79 | 2019-2023 | Keytruda, Lynparza |
| Integra Gpo, LLC | $5,895.15 | 2019 | |
| Urogen Pharma, INC. | $5,323.61 | 2021-2024 | |
| Clovis Oncology, INC. | $4,897.50 | 2019-2020 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $3,267.38 | 2019-2025 | Adstiladrin |
| Janssen Scientific Affairs, LLC | $2,358.96 | 2021-2025 | Akeega, Pipeline, Erleada |
| Antares Pharma, INC. | $1,810.27 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Verity Pharmaceuticals INC. | $1,694.38 | 2021-2025 | Trelstar |
| Blue Earth Diagnostics | $600.73 | 2022-2025 | Posluma |
| Novo Nordisk INC | $595.00 | 2023 | |
| Myriad Genetic Laboratories, INC. | $509.80 | 2021-2025 | Prolaris, Myrisk |
| Dendreon Pharmaceuticals LLC | $427.34 | 2019-2025 | Provenge |
| Teleflex LLC | $420.22 | 2021-2025 | Urolift, Barrigel |
| Cook Incorporated | $400.00 | 2025 | |
| Karl Storz Endoscopy-America | $304.21 | 2019-2023 | Flex-X / Image 1 S, Hd-View |
| Dornier Medtech America, INC | $228.42 | 2025 | Dornier Medtech |
| Johnson & Johnson Health Care Systems INC. | $160.90 | 2025 | Erleada |
| Tolmar, INC. | $153.82 | 2024-2025 | Eligard, Jatenzo |
| Comsort, INC | $100.00 | 2019 | |
| Urovant Sciences INC | $98.37 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $75.86 | 2023-2024 | Orgovyx, Gemtesa |
| Telix Pharmaceuticals | $69.38 | 2023-2024 | Illuccix |
| Allergan, INC. | $69.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.86 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $64.79 | 2023 | Givlaari |
| Coloplast Corp | $60.65 | 2020-2022 | |
| Procept Biorobotics Corporation | $59.80 | 2023-2025 | Aquabeam Robotic System |
| Avyxa Pharma, LLC | $54.25 | 2025 | |
| Ethicon Endo-Surgery INC. | $53.64 | 2024 | |
| Endo Pharmaceuticals INC. | $53.12 | 2020-2021 | |
| Hollister Incorporated | $50.61 | 2021-2022 | |
| Accord Healthcare, INC. | $47.20 | 2022 | |
| Immunitybio, INC. | $39.06 | 2024 | |
| Amgen INC. | $38.77 | 2019 | |
| Intrinsiq Specialty Solutions, INC. | $38.11 | 2024 | |
| Acerus Pharmaceuticals Corporation | $34.37 | 2021-2022 | |
| Astellas Pharma Global Development | $33.32 | 2019-2024 | Xtandi |
| Foundation Medicine, INC. | $30.65 | 2020-2022 | |
| C. R. Bard, INC. & Subsidiaries | $24.64 | 2019 | |
| Palette Life Sciences, INC. | $16.59 | 2022 | |
| Olympus America INC. | $16.43 | 2023 | Itind System |
| Clarus Therapeutics INC. | $15.95 | 2021 | |
| Neotract INC. | $14.53 | 2019 | |
| Laborie Medical Technologies Corp. | $13.67 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Cook Medical LLC | $12.84 | 2019 | |
| Uroviu Corporation | $12.50 | 2022 | |
| Escala Medical INC. | $9.45 | 2025 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$609.98 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Goldfischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.